latest update:
[TrialBase DB]

trial summary · NCT06807021

Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double- Blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Mitigation of Cutaneous Scarring in Skin Graft and Donor Sites in Burn Patients

Trial record from the TrialBase DB dataset, status RECRUITING, condition Burn Scar, sponsored by Birch BioMed Inc. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06807021phase PHASE2/PHASE3enrollment 70start 2027-03

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this study is to see how an ingredient called kynurenic acid (which we named "FS2") affects scar formation in people with burn injuries that need skin graft surgery. A cream with FS2 will be used on both the area where the skin graft was placed and the area where the skin was taken (donor site). The cream will be applied after the skin has healed. This study will help us understand if FS2 is safe and effective for mitigating skin scar formation in burn patients.

Source record: https://clinicaltrials.gov/study/NCT06807021

Facts

registry idNCT06807021
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2/PHASE3
study typeINTERVENTIONAL
lead conditionBurn Scar
sponsorBirch BioMed Inc
sponsor classINDUSTRY
enrollment70
start date2027-03
primary completion2027-09
completion2027-09
results postednot reported

Conditions

  • Burn Scar
  • Burn Wound

Interventions

  • IP1 control cream (Vehicle base)
  • IP2 - 0.5% w/w FS2

Countries

  • Canada

Intervention types: DRUG

Work with this record